For richer charts and full features, open SpikePanel on desktop.
Graded daily on value D-, growth C+, profitability C-, momentum B, revisions A-. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $NKTR are available with SpikePanel Pro.
Key events, in time order
EADV data show sustained hair regrowth after stopping, supporting Phase III trial
Federal jury finds Lilly breached implied covenant; award subject to post-trial and appeal
FDA grants single AA Phase 3 path, AtD program doubles as safety database, reducing trials
Q2 loss beat but revenue missed; cash strong; Phase 3 ZENITH-AD underway, data mid-2028
LLY lawyers push for BD/partnership docs post-Feb 2026; pretrial battle intensifies
rezpeg治疗中重度特应性皮炎的全球III期ZENITH AD项目已于7月启动,前两项研究开始随机入组,第三项研究预计9月底启动;顶线数据预计2028年中读出,若阳性则2029年提交BLA。
Quarterly results provide updates on financials and pipeline progress.
Stock gapped from $69.36 to $73.31, reflecting positive market sentiment on Rezpeg prospects
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice